Avalo Therapeutics, Inc.
AVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.02 | 0.27 |
| FCF Yield | -81.23% | -1,220.19% | -56.61% | -40.07% |
| EV / EBITDA | 1.08 | 0.19 | -1.45 | -1.94 |
| Quality | ||||
| ROIC | -47.47% | -161.73% | -211.35% | -134.75% |
| Gross Margin | 182.99% | 33.26% | 80.98% | 72.38% |
| Cash Conversion Ratio | 1.40 | 0.97 | 0.64 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.98% | -29.10% | 39.15% | -7.18% |
| Free Cash Flow Growth | -59.08% | -14.87% | 62.19% | -74.88% |
| Safety | ||||
| Net Debt / EBITDA | 1.96 | 0.30 | -0.18 | 0.26 |
| Interest Coverage | 0.00 | -8.00 | -8.98 | -34.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 171.70 | 39.24 |
| Cash Conversion Cycle | 787.93 | -100.98 | -265.40 | -490.94 |